Skip to content

Author

T. Utriainen

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.

PURPOSE Patients with metastatic castration-resistant prostate cancer (mCRPC) and advanced breast cancer (aBC) have poor outcomes with standard treatments. We report phase 1 results from the STESIDES (NCT03878823) study of ODM-209, an oral selective CYP11A1 inhibitor that blocks all synthesis of steroid hormones. MET...

A. Bernard-Tessier, I. Spanggaard, T. Utriainen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.